Johnson & Johnson's Q2 2012 earnings call highlights moderate operational growth, despite currency headwinds and generic competition.  Management emphasizes a long-term strategy focused on innovation, global expansion, and execution excellence.  While concerns about the OTC business are addressed, the call presents an optimistic view of the future, especially considering planned integration of Synthes.
[1]
